Home FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents
 

Keywords :   


FDA Approves Pediatric Indication for EMEND (aprepitant) Capsules in Combination with Other Antiemetic Agents

2015-09-02 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. Language: English Contact: MerckMedia:Doris Li, 908-740-1903An Phan, 908-255-6325orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: combination agents indication pediatric

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
22.11Spain fines budget airlines including Ryanair 179m
22.11Eastern North Pacific Tropical Weather Outlook
22.11Atlantic Tropical Weather Outlook
22.11Rush PANTS
22.11SBS
22.11/
22.11 YOU
22.11
More »